Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study

NCT05008237 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
42
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Samsung Medical Center